Arena Pharmaceuticals (ARNA) Slammed on Massive 'Bear Raid'
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
The biggest momo stock in the market Arena Pharmaceuticals (Nasdaq: ARNA) was just the target of a massive "bear raid."
Shares plunged as low as $7.80, or down 33%, before recovering.
There is no new news, but with the 6/27 PDUFA date fast approaching investors are getting nervous with the current news vacuum.
This has been seen before in stocks like Dendreon Corp. (Nasdaq: DNDN) days before FDA approval was ultimately granted.
Shares plunged as low as $7.80, or down 33%, before recovering.
There is no new news, but with the 6/27 PDUFA date fast approaching investors are getting nervous with the current news vacuum.
This has been seen before in stocks like Dendreon Corp. (Nasdaq: DNDN) days before FDA approval was ultimately granted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
